Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

被引:98
作者
Dunleavy, Kieron [1 ]
Wilson, Wyndham H. [1 ]
机构
[1] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
NON-HODGKINS-LYMPHOMA; REED-STERNBERG CELLS; DOSE-ADJUSTED EPOCH; CD23; EXPRESSION; CHEMOTHERAPY; RITUXIMAB; CHOP; FEATURES; JAK2; AMPLIFICATION;
D O I
10.1182/blood-2014-05-575092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary mediastinal B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) that is putatively derived from a thymic B cell. Accounting for up to 10% of cases of DLBCL, this subtype predominantly affects women in the third and fourth decades of life. Its clinical and molecular characteristics are distinct from other subtypes of DLBCL and, in fact, closely resemble those of nodular sclerosing Hodgkin lymphoma (NSHL). Recently, mediastinal lymphomas with features intermediate between PMBL and NSHL, called mediastinal gray-zone lymphomas, have been described. The optimal management of PMBL is controversial, and most standard approaches include a combination of immunochemotherapy and mediastinal radiation. Recently, the recognition that mediastinal radiation is associated with significant long-term toxicities has led to the development of novel approaches for PMBL that have shown excellent efficacy and challenge the need for routine mediastinal radiation.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 52 条
[1]   Therapy in Primary Mediastinal B-Cell Lymphoma [J].
不详 .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :282-284
[2]   The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma [J].
Avigdor, Abraham ;
Sirotkin, Tsvi ;
Kedmi, Meirav ;
Ribakovsy, Elena ;
Berkowicz, Miriam ;
Davidovitz, Yaron ;
Kneller, Abraham ;
Merkel, Drorit ;
Volchek, Yulia ;
Davidson, Tima ;
Goshen, Elinor ;
Apter, Sara ;
Shimoni, Avichai ;
Ben-Bassat, Isaac ;
Nagler, Arnon .
ANNALS OF HEMATOLOGY, 2014, 93 (08) :1297-1304
[3]   Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].
Berger, Raanan ;
Rotem-Yehudar, Rinat ;
Slama, Gideon ;
Landes, Shimon ;
Kneller, Abraham ;
Leiba, Merav ;
Koren-Michowitz, Maya ;
Shimoni, Avichai ;
Nagler, Arnon .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051
[4]   CD23 expression in mediastinal large B-cell lymphomas [J].
Calaminici, M ;
Piper, K ;
Lee, AM ;
Norton, AJ .
HISTOPATHOLOGY, 2004, 45 (06) :619-624
[5]   Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study [J].
Castellino, Sharon M. ;
Geiger, Ann M. ;
Mertens, Ann C. ;
Leisenring, Wendy M. ;
Tooze, Janet A. ;
Goodman, Pam ;
Stovall, Marilyn ;
Robison, Leslie L. ;
Hudson, Melissa M. .
BLOOD, 2011, 117 (06) :1806-1816
[6]   Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87) -: A GELA study [J].
Cazals-Hatem, D ;
André, M ;
Mounier, N ;
Copin, MC ;
Divine, M ;
Berger, F ;
Bosly, A ;
Kerneis, Y ;
Brière, J ;
Quesnel, B ;
Diebold, J ;
Gaulard, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) :297-306
[7]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[8]   U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma [J].
de Claro, R. Angelo ;
McGinn, Karen ;
Kwitkowski, Virginia ;
Bullock, Julie ;
Khandelwal, Aakanksha ;
Habtemariam, Bahru ;
Ouyang, Yanli ;
Saber, Haleh ;
Lee, Kyung ;
Koti, Kallappa ;
Rothmann, Mark ;
Shapiro, Marjorie ;
Borrego, Francisco ;
Clouse, Kathleen ;
Chen, Xiao Hong ;
Brown, Janice ;
Akinsanya, Lara ;
Kane, Robert ;
Kaminskas, Edvardas ;
Farrell, Ann ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2012, 18 (21) :5845-5849
[9]  
Dunleavy K., 2011, Annals Oncol, V22
[10]   Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma [J].
Dunleavy, Kieron ;
Pittaluga, Stefania ;
Maeda, Lauren S. ;
Advani, Ranjana ;
Chen, Clara C. ;
Hessler, Julie ;
Steinberg, Seth M. ;
Grant, Cliona ;
Wright, George ;
Varma, Gaurav ;
Staudt, Louis M. ;
Jaffe, Elaine S. ;
Wilson, Wyndham H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15) :1408-1416